EDITORIAL   |  November 30, 2019   Perioperative Study of Vorasidenib Shows Promise for Patients with Low-Grade Glioma A perioperative study in low-grade glioma with an IDH1 mutation suggested brain penetrance and robust biomarker suppression with treatment of single agent vorasidenib or ivosidenib. Read more   FDA Accepts Biologics License Application for Bevacizumab Biosimilar The FDA has accepted a biologics license application under the 351(k) pathway for SB8, a biosimilar candidate for bevacizumab. Read more

IN CASE YOU MISSED IT

Expert Discusses Service Focused on Immunotherapy-Related AEs Kerry Reynolds, MD, discussed the increase in immunotherapy-related adverse events, specifically in renal cell carcinoma.